Popular on PrZen
- Los Angeles Fires: Supporting Recovery Without Psychotropic Drug Risks - 253
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control" - 183
- SlotCycle Raises $5.6M to Transform Secondary Gaming Equipment Market, Led by Discerning Capital - 165
- ®Grammy Award Winner Alex Cuba releases new single "El Día Más Triste" - 146
- LAIIER Closes Oversubscribed US$4M Seed Extension Funding Round, Led by Closed Loop Partners - 101
- Franchising Success, One Pour at a Time - 101
- Greg Welch Joins Calovia as Managing and Founding Partner
- Alliance Homecare Appoints Amy Romero as CMO to Drive Growth of TrustHouse, Private In-Home Nursing and Concierge Care
- Connected Technologies Delivers Cutting-Edge Technology to Landmark Properties' Student Housing Communities
- The Power Of Online Reviews & Why They Matter
Similar on PrZen
- Breaking Barriers: The Black Therapy Network is Closing the Mental Health Gap for Black Americans
- AdvisorVault Now Combines Microsoft 365 with their 17a-4 D3P Service
- MSM Advisors CPAs and Small Business Advisors Recognized as 'Among the Best of Gwinnett' in 2024
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
- Super Locksmith Saint Petersburg
- Maryland Bill Aims to Curb Mental Health Youth Transport Abuses
- Jazz Legend Bob Holz Nomination-New Album Honoring Larry Coryell
- Aterna AI Introduces Automated Investing Software for Entrepreneurs Focused on Reliable Growth
- Rutgers University Student Wins "New Jersey's Top Student Entrepreneur" in EO's Global Student Entrepreneur Awards
- Global Digital Currency & Wealth Management Leader; Breakout 388% FY2025 Revenue Growth Over $19.7 Million: Metalpha Technology (Stock Symbol: MATH)
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
PrZen/33554948
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - PrZen -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on PrZen
- Breaking Barriers: The Black Therapy Network is Closing the Mental Health Gap for Black Americans
- AdvisorVault Now Combines Microsoft 365 with their 17a-4 D3P Service
- MSM Advisors CPAs and Small Business Advisors Recognized as 'Among the Best of Gwinnett' in 2024
- Unlock the Hidden Power of Dreams in The Lucid War Chronicles
- AAGLA Signs With CredHub to Help Owners Comply with New Rent Reporting Requirements
- Hardwood or Tile? A Homeowner's Guide to Choosing the Right Flooring
- Explore the "Magic of Rainbows" in the New Children's Book Series "Mila and Ally's STEMventures
- Relentless 2800 Challenge: A 40-Day Team Fitness Journey Launching for Lent 2025
- Super Locksmith In Tampa Florida
- Super Locksmith Saint Petersburg
- Maryland Bill Aims to Curb Mental Health Youth Transport Abuses
- INDEPENDENT PRESS AWARD® announces the 2025 winners
- Evolution of an Outdoor Essential
- DAY Miner: Using AI to transform cryptocurrency mining, boost revenue by 30%
- Jazz Legend Bob Holz Nomination-New Album Honoring Larry Coryell
- Aterna AI Introduces Automated Investing Software for Entrepreneurs Focused on Reliable Growth
- Rutgers University Student Wins "New Jersey's Top Student Entrepreneur" in EO's Global Student Entrepreneur Awards
- Global Digital Currency & Wealth Management Leader; Breakout 388% FY2025 Revenue Growth Over $19.7 Million: Metalpha Technology (Stock Symbol: MATH)
- InterMountain Opens Urban Inspired Aloft Sacramento Airport Natomas
- Cura HR's CEO, Lyssa Hansard, Featured in Forbes: Driving Meaningful Change in Pay Equity